MBX Biosciences is trading 4.3% lower at $59.32, with no confirmed company-specific announcement identified for September 23, 2026. - Its investor-relations page lists its latest release on September 9. - Recent coverage focused on the September 16 Morgan Stanley healthcare conference and upcoming clinical milestones. - Broader equities are weaker, but biotechnology is outperforming, so market and sector conditions do not clearly explain the decline. The specific catalyst remains unconfirmed.